Halozyme Therapeutics Inc
NASDAQ:HALO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
US |
|
T
|
Thales SA
SWB:CSF
|
FR |
|
S
|
Stagwell Inc
F:6IY
|
US |
|
F
|
Fuyo General Lease Co Ltd
F:FXL
|
JP |
|
A
|
Ardmore Shipping Corp
F:A61
|
BM |
|
E
|
Everyday People Financial Corp
XTSX:EPF
|
CA |
|
Brioschi Sviluppo Immobiliare SpA
MIL:BRI
|
IT |
|
L
|
Live Nation Entertainment Inc
SWB:3LN
|
US |
|
Impax Asset Management Group PLC
LSE:IPX
|
UK |
|
Kansai Paint Co Ltd
TSE:4613
|
JP |
|
Advantest Corp
OTC:ADTTF
|
JP |
|
O
|
Organigram Global Inc
F:0OG
|
CA |
|
V
|
Verbio SE
SWB:VBK
|
DE |
|
Repay Holdings Corp
NASDAQ:RPAY
|
US |
|
Seche Environnement SA
PAR:SCHP
|
FR |
|
S
|
Sporting Clube de Portugal Futebol SAD
SWB:SCG
|
PT |
|
D
|
DCC PLC
OTC:DCCPF
|
IE |
|
C
|
China Pacific Insurance Group Co Ltd
XMUN:75C
|
CN |
|
A
|
Autohome Inc
F:8AHB
|
CN |
|
S
|
SSR Mining Inc
DUS:ZSV
|
US |
|
Duolingo Inc
NASDAQ:DUOL
|
US |
|
Cham Swiss Properties AG
F:4U3
|
CH |
|
S
|
Sun Communities Inc
F:SCZ
|
US |
|
Pro-Dex Inc
NASDAQ:PDEX
|
US |
Intrinsic Value
Is HALO undervalued or overvalued?
See the intrinsic value estimate for Halozyme Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Halozyme Therapeutics Does
Halozyme Therapeutics makes drug-delivery technology that helps injectable medicines move from an IV infusion to a shot under the skin. Its core product is a recombinant enzyme used with partner drugs so patients can receive certain therapies faster and more conveniently in outpatient settings. The company also develops and sells this enzyme in forms used by its pharmaceutical partners and in hospital care.
- Headquarters
- United States of America US
- Employees
- 423
- IPO date
- Jan 30, 2003
Halozyme Therapeutics has a wide economic moat
Patent protection keeps rivals from freely copying Halozyme’s injection technology, while its inclusion in approved medicines makes replacement costly and time-consuming. Together, these barriers help Halozyme retain drug-company partners and collect payments tied to their medicine sales.
Read the full moat analysis
Revenue & Expenses Breakdown
Halozyme Therapeutics Inc
Earnings Waterfall
Halozyme Therapeutics Inc
The intrinsic value for Halozyme Therapeutics Inc (HALO) under the Base Case is hidden USD.
Compared with the current market price of 130.915 USD, the stock appears hidden.